Alken
Alken
Alken, Belgium15 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia | Disorders of Excessive Somnolence, Dyssomnias, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Sleep Disorders, Intrinsic, idiopathic hypersomnia, narcolepsy, narcolepsy without cataplexy, narcolepsy-cataplexy syndrome, nervous system disorder, psychiatric disorder, sleep-wake disorder | Recruiting | Phase 2 / Phase 3 | 2026-10-09 | NCT06767683 | |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Arterial Occlusive Diseases, Chronic Disease, Death, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, arteriosclerosis disorder, atherosclerosis, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, chronic renal failure syndrome, coronary artery disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, kidney disorder, kidney failure, metabolic disease, myocardial ischemia, nervous system disorder, peripheral arterial disease, peripheral vascular disease, type 2 diabetes mellitus, urinary system disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT06383390 | |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus | Recruiting | Phase 3 | 2026-09-30 | NCT07564414 | |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Nutritional and Metabolic Diseases, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hypertensive disorder, metabolic disease, type 2 diabetes mellitus, vascular disorder | Recruiting | Phase 3 | 2026-09-30 | NCT07064473 | |
| Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | Psychosis Associated With Alzheimer's Disease | Recruiting | Phase 3 | 2026-09-29 | NCT05980949 | |
| A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | Disorders of Excessive Somnolence, Dyssomnias, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Sleep Disorders, Intrinsic, idiopathic hypersomnia, nervous system disorder, psychiatric disorder, sleep-wake disorder | Active, not recruiting | Phase 2 | 2026-09-25 | NCT06843590 | |
| Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Recruiting | Phase 3 | 2026-09-24 | NCT07157774 | |
| A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Alzheimer disease, Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-09-22 | NCT06585787 | |
| Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-09-09 | NCT07770841 | |
| NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-08-10 | NCT06963021 | |
| Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-07-24 | NCT06966401 | |
| A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis With Nasal Polyps | Active, not recruiting | Phase 3 | 2026-06-02 | NCT06834360 | |
| A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age | DNA Virus Infections, Herpesviridae infectious disease, Infections, Varicella Zoster Virus Infection, chickenpox, viral infectious disease | Recruiting | Phase 3 | 2026-05-29 | NCT06855160 | |
| A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy | Disorders of Excessive Somnolence, Dyssomnias, Sleep Disorders, Intrinsic, narcolepsy, nervous system disorder, psychiatric disorder, sleep-wake disorder | Recruiting | Phase 2 | 2026-05-14 | NCT07493265 | |
| Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age | Healthy Volunteers; Pneumococcal Immunization | Active, not recruiting | Phase 3 | 2026-03-02 | NCT06975878 |